

ALL WITHIN SPECIFICATION

Retatrutide (RETA-3)



ACCESS CODE

AXQTDLDA

RELEASED

25 September 2026

ISSUED TO

BioMetrixLabs

SAMPLE

Retatrutide (RETA-3)

LOT NUMBER

BXL-2609-RT20-01

BATCH NUMBER

B-2026-0742

ACCESSION NUMBER

ACC-2026-00742

LABELLED AMOUNT

20 mg

CONDITION AT RECEIPT

Sealed, crimped, cap intact

DATE RECEIVED

21 September 2026


DATE OF ANALYSIS

24 September 2026

VIAL AS RECEIVED

REPORTED PURITY METRIC (AREA %)

Acceptance $\geq$ 95%



SUMMARY OF RESULTS

Identity

Conforms - identity confirmed

PASS

Purity

99.1%

PASS

Net content

20.8 mg / vial (104.0% of label)

PASS

Bacterial endotoxins

PASS

PASS

Heavy metals

PASS

PASS



ACC-2026-00742

A. Beaulieu

Analyst named in supplied source COA

Original release: 25 September 2026

ALL ANALYSES

ANALYSIS	METHOD	RESULT	SPECIFICATION	VERDICT
Identity	LC-MS (ESI+)	Conforms - identity confirmed	Consistent with reference	PASS
Purity	RP-HPLC-UV - area normalisation	99.1%	≥95.0%	PASS
Net content	Quantitative HPLC vs reference standard	20.8 mg / vial (104.0% of label)	20 mg ± 10%	PASS
Bacterial endotoxins	LAL - USP <85>	PASS	Within specification	PASS
Heavy metals	ICP-MS	PASS	ICH Q3D limits	PASS

NOTES

Results apply only to the vial submitted, as received, on the dates stated. Purity is reported as area percent; net content is the measured amount per vial against the labelled 20 mg. Bacterial endotoxins and heavy metals are reported as PASS in the supplied COA. Numerical results or individual analyte concentrations were not provided. This reformatted copy adds no analytical determination, raw chromatogram, or analyst signature.

SCOPE AND LIMITATIONS

This certificate applies only to the sample submitted, as received, on the stated dates. It says nothing about another vial, lot, batch, or product. It is not a marketing authorisation, health product licence, DIN, NPN, FDA clearance, or approval, and makes no statement of safety, efficacy, or fitness for any purpose. Research and quality-control use only. Accreditation status in the source: ISO/IEC 17025:2017 - in progress.



AXQTDLDA

Source report ASL-2026-000742; received 21 September 2026; analysis 24 September 2026; original release 25 September 2026. Reformatted from the supplied source COA.

A. Beaulieu

Analyst identified in supplied COA